Last reviewed · How we verify

Topical betamethasone 0.05%

Post Graduate Institute of Medical Education and Research, Chandigarh · FDA-approved active Small molecule Quality 5/100

Topical betamethasone 0.05% is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh. It is currently FDA-approved.

At a glance

Generic nameTopical betamethasone 0.05%
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical betamethasone 0.05%

What is Topical betamethasone 0.05%?

Topical betamethasone 0.05% is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh.

Who makes Topical betamethasone 0.05%?

Topical betamethasone 0.05% is developed and marketed by Post Graduate Institute of Medical Education and Research, Chandigarh (see full Post Graduate Institute of Medical Education and Research, Chandigarh pipeline at /company/post-graduate-institute-of-medical-education-and-research-chandigarh).

What development phase is Topical betamethasone 0.05% in?

Topical betamethasone 0.05% is FDA-approved (marketed).

Related